Capsugel plans to expand its facility in Edinburgh, Scotland for pharmaceutical product development and commercial manufacturing services. The company will more than double the size of its Edinburgh facility by adding 40,000 square feet of space. The expansion will enable Capsugel's Dosage Form Solutions business unit to both increase its liquid- and semi-solid-fill hard capsule manufacturing capacity for drug products containing high-potency active pharmaceutical ingredients (HPAPIs) and further diversify its technology platforms offered at the facility.

The Edinburgh facility was acquired by Capsugel as part of its purchase of Encap Drug Delivery in March 2013. The first phase of the expansion includes new analytical, formulation, and quality laboratories for meeting demand for bioavailability, HPAPI and other formulation services. The second phase, which is scheduled to begin later in 2015, will expand commercial manufacturing capacity for the site's existing technologies and bring the company's other formulation and development technologies, including spray dried dispersion (SDD), to this location. Similar to Capsugel's SDD center of excellence at its facility in Bend, Ore., the company's SDD offering in Europe will eventually include development through commercial-scale capabilities.

Source: Capsugel